Access the full text.
Sign up today, get DeepDyve free for 14 days.
Tao Wang, E. Hsieh, P. Henry, W. Hanna, C. Streutker, A. Grin (2014)
Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status.Human pathology, 45 5
Hedyeh Shafi, Kristine Astvatsaturyan, F. Chung, J. Mirocha, Michael Schmidt, S. Bose (2013)
Clinicopathological significance of HER2/neu genetic heterogeneity in HER2/neu non-amplified invasive breast carcinomas and its concurrent axillary metastasisJournal of Clinical Pathology, 66
Martin Chang, Janet Malowany, Julita Mazurkiewicz, M. Wood (2012)
‘Genetic heterogeneity’ in HER2/neu testing by fluorescence in situ hybridization: a study of 2522 casesModern Pathology, 25
Y. Bang, E. Cutsem, A. Feyereislova, H. Chung, L. Shen, A. Sawaki, F. Lordick, A. Ohtsu, Y. Omuro, T. Satoh, G. Aprile, E. Kulikov, Julie Hill, M. Lehle, J. Rüschoff, Yoon-Koo Kang (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 376
L. Albarello, L. Pecciarini, C. Doglioni (2011)
HER2 Testing in Gastric CancerAdvances in Anatomic Pathology, 18
Jiyuan Yang, He-Shen Luo, Yan Li, Junchuan Li, Z. Cai, Xiao-lin Su, Da-nian Dai, W. Du, Tingxuan Chen, Ming Chen (2011)
Intratumoral Heterogeneity Determines Discordant Results of Diagnostic Tests for Human Epidermal Growth Factor Receptor (HER) 2 in Gastric Cancer SpecimensCell Biochemistry and Biophysics, 62
Stephen Lee, W. Boer, S. Fermoyle, M. Platten, M. Kumarasinghe (2011)
Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections *Histopathology, 59
M. Ness, J. Gregg, Jun Wang, Mingyi Chen (2012)
Genetics and molecular pathology of gastric malignancy: Development of targeted therapies in the era of personalized medicine.Journal of gastrointestinal oncology, 3 3
J. Rüschoff, W. Hanna, M. Bilous, M. Hofmann, R. Osamura, F. Penault-Llorca, M. Vijver, G. Viale (2012)
HER2 testing in gastric cancer: a practical approachModern Pathology, 25
Alastair Bartlett, J. Starcyznski, T. Robson, A. MacLellan, Fiona Campbell, C. Velde, A. Hasenburg, C. Markopoulos, C. Seynaeve, D. Rea, J. Bartlett (2011)
Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition.American journal of clinical pathology, 136 2
Antonio Wolff, M. Hammond, David Hicks, M. Dowsett, Lisa McShane, Kimberly Allison, D. Allred, John Bartlett, M. Bilous, P. Fitzgibbons, W. Hanna, Robert Jenkins, P. Mangu, S. Paik, Edith Perez, Michael Press, Patricia Spears, Gail Vance, G. Viale, Daniel Hayes (2014)
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.Archives of pathology & laboratory medicine, 138 2
M. Hofmann, O. Stoss, D. Shi, R. Büttner, M. Vijver, Woosuk Kim, A. Ochiai, J. Rüschoff, T. Henkel (2008)
Assessment of a HER2 scoring system for gastric cancer: results from a validation studyHistopathology, 52
G. Vance, T. Barry, K. Bloom, P. Fitzgibbons, D. Hicks, R. Jenkins, D. Persons, R. Tubbs, M. Hammond (2009)
Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines.Archives of pathology & laboratory medicine, 133 4
T. Oliphant (2007)
Python for Scientific ComputingComputing in Science & Engineering, 9
W. Hanna, J. Rüschoff, M. Bilous, R. Coudry, M. Dowsett, R. Osamura, F. Penault-Llorca, M. Vijver, G. Viale (2014)
HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneityModern Pathology, 27
C. Öhlschlegel, K. Zahel, D. Kradolfer, M. Hell, W. Jochum (2011)
HER2 genetic heterogeneity in breast carcinomaJournal of Clinical Pathology, 64
RESEARCH ARTICLE HER2 Genetic Heterogeneity in Gastric Cancer: Evaluation According to the College of American Pathologists Breast Cancer Criteria Ann D. Treacy, MB, MRCPI, FRCPath, FFPath, Jason R. Karamchandani, MD, Catherine J. Streutker, MSc, MD, FRCP(C), and Andrea Grin, MD, FRCP(C) astric cancer is the fourth most common cancer Abstract: Gastric and gastroesophageal junction (GEJ) ad- Gworldwide and is the second most common cause of enocarcinomas have been shown to display significant HER2 cancer-related death. Although advances have been genetic heterogeneity (GH). This is typically seen as a cluster of made in the diagnosis and treatment of gastric and gas- HER2-positive cells but can also take the form of intermingled troesophageal junction (GEJ) adenocarcinoma, the cells, referred to a “mosaic” pattern. GH is not well defined in prognosis of advanced-stage adenocarcinomas remains gastric/GEJ tumors and the “mosaic” pattern has never been poor. In the era of personalized medicine, the role of studied. We sought to evaluate the frequency and distribution of HER2 in gastric/GEJ cancer has been widely welcomed 2,3 the “mosaic” pattern of GH in gastric/GEJ tumors using the as a promising development in cancer treatment. College of American Pathologists-endorsed breast criteria of 5% Approximately 7% to 34%
Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health
Published: Jan 1, 2015
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.